BioCardia Inc
BCDA1.330USD
0.000
Cierre 11/04, 16:00（ET）Cotizaciones retrasadas 15 min
7.32MCap. mercado
PérdidaP/E TTM
Más Datos de BioCardia Inc Compañía
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Información de BioCardia Inc
Símbolo de cotizaciónBCDA
Nombre de la empresaBioCardia Inc
Fecha de salida a bolsaNov 13, 1996
Director ejecutivoDr. Peter Altman, Ph.D.
Número de empleados17
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 13
Dirección320 Soquel Way
CiudadSUNNYVALE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94085
Teléfono16502260123
Sitio Webhttps://www.biocardia.com/
Símbolo de cotizaciónBCDA
Fecha de salida a bolsaNov 13, 1996
Director ejecutivoDr. Peter Altman, Ph.D.
Ejecutivos de BioCardia Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
218.60K
+28.14%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Mr. Bill Facteau
Mr. Bill Facteau
Independent Director
Independent Director
13.12K
--
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Independent Director
Independent Director
3.62K
-0.06%
Mr. Edward Gillis
Mr. Edward Gillis
Senior Vice President - Devices
Senior Vice President - Devices
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
218.60K
+28.14%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 30 de oct
Actualizado: jue., 30 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lincoln Alternative Strategies LLC
7.54%
Satterfield (Thomas A Jr)
3.17%
Stertzer (Simon H)
2.54%
Altman (Peter)
2.06%
Blank (Andrew Scott)
1.36%
Otro
83.33%
Accionistas
Accionistas
Proporción
Lincoln Alternative Strategies LLC
7.54%
Satterfield (Thomas A Jr)
3.17%
Stertzer (Simon H)
2.54%
Altman (Peter)
2.06%
Blank (Andrew Scott)
1.36%
Otro
83.33%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
11.01%
Corporation
8.91%
Investment Advisor
2.32%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.02%
Otro
77.05%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
37
321.59K
3.03%
-83.67K
2025Q2
51
1.43M
26.27%
+378.18K
2025Q1
56
1.40M
27.94%
+375.61K
2024Q4
58
1.08M
23.60%
+180.41K
2024Q3
57
740.61K
21.37%
-175.94K
2024Q2
60
625.47K
23.03%
-304.05K
2024Q1
60
735.85K
38.95%
-141.63K
2023Q4
61
789.41K
56.72%
+313.00
2023Q3
59
767.08K
57.64%
+35.10K
2023Q2
59
692.26K
54.51%
+36.66K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lincoln Alternative Strategies LLC
800.00K
7.54%
+800.00K
--
Sep 19, 2025
Satterfield (Thomas A Jr)
336.00K
3.17%
-52.15K
-13.44%
Jun 30, 2025
Stertzer (Simon H)
118.69K
2.54%
+39.29K
+49.48%
Mar 05, 2025
Altman (Peter)
218.60K
2.06%
+48.00K
+28.14%
Sep 19, 2025
Blank (Andrew Scott)
144.54K
1.36%
--
--
Apr 23, 2025
CM Management, LLC
130.00K
1.23%
+55.00K
+73.33%
Jun 30, 2025
Allen (Jim L)
109.66K
1.03%
-1.00
-0.00%
Dec 31, 2024
Frost Gamma Investments Trust
85.76K
0.81%
-18.98K
-18.12%
Mar 26, 2024
Stertzer Family Trust
59.20K
0.56%
-2.00
-0.00%
Dec 31, 2024
Mcclung (David)
47.95K
0.45%
+4.82K
+11.17%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
Fecha
Tipo
Relación
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
